A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

NCT05395533 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

CD20-positive B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: Recombinant CD20 monoclonal antibody-MMAE conjugte for injection

Sponsor

Zhejiang Teruisi Pharmaceutical Inc.